Dyne Therapeutics is a clinical-stage biotechnology company dedicated to advancing transformative therapies for genetically driven neuromuscular diseases. The company leverages its proprietary FORCE platform, which utilizes the transferrin receptor 1, or TfR1, to deliver targeted therapeutics directly to muscle tissue and the central nervous system. This innovative approach combines a TfR1-binding antigen-binding fragment antibody with rationally designed payloads, such as oligonucleotides and enzymes, to address the underlying genetic causes of diseases like Duchenne muscular dystrophy, myotonic dystrophy type 1, facioscapulohumeral dystrophy, and Pompe disease. Dyne Therapeutics focuses on diseases with high unmet medical needs, clear translational potential from preclinical models, and well-defined clinical and regulatory pathways.
Dyne Therapeutics generates revenue through the development and eventual commercialization of its investigational therapies. The company’s primary revenue streams will stem from the sale of approved treatments for neuromuscular diseases, though it has not yet commercialized any products. Key product candidates include z-rostudirsen for Duchenne muscular dystrophy amenable to exon 51 skipping, and z-basivarsen for myotonic dystrophy type 1, both of which are in registrational clinical trials. The company plans to submit biologics license applications for these candidates in 2026 and 2027, respectively, with potential U. S. launches in 2027 and 2028. Additional revenue may arise from strategic collaborations, licensing agreements, or partnerships aimed at expanding the application of its FORCE platform to other indications.
The company operates through the following segments:
- Duchenne Muscular Dystrophy (DMD) Program: This segment focuses on developing therapies for DMD, a severe genetic disorder caused by mutations in the dystrophin gene. Dyne Therapeutics’ lead candidate, z-rostudirsen (DYNE-251), is designed to promote exon 51 skipping, enabling the production of a more functional dystrophin protein. The program includes additional candidates targeting exons 53, 45, 44, and 55, all leveraging the FORCE platform to enhance muscle delivery and clinical efficacy. Z-rostudirsen is currently in a global Phase 1/2 registrational trial, with plans for a biologics license application submission in the second quarter of 2026.
- Myotonic Dystrophy Type 1 (DM1) Program: This segment targets DM1, a progressive multisystemic disorder caused by toxic nuclear DMPK RNA. The lead candidate, z-basivarsen (DYNE-101), is an antisense oligonucleotide conjugated to the FORCE platform, designed to reduce toxic RNA levels and restore normal splicing. Z-basivarsen is being evaluated in the global Phase 1/2 ACHIEVE trial, with topline data expected in 2027 and a potential biologics license application submission in the third quarter of 2027.
- Facioscapulohumeral Dystrophy (FSHD) Program: This segment aims to address FSHD, a disease characterized by aberrant expression of the DUX4 gene in muscle tissue. Dyne Therapeutics’ candidate, DYNE-302, utilizes a small interfering RNA payload to suppress DUX4 expression. Preclinical studies have demonstrated robust and durable DUX4 suppression and functional benefits in disease models, with plans to advance DYNE-302 toward clinical development.
- Pompe Disease Program: This segment focuses on Pompe disease, a rare disorder caused by a deficiency of the lysosomal enzyme acid alpha-glucosidase. The company’s candidate, DYNE-401, leverages the FORCE platform to deliver enzyme replacement therapy directly to muscle and central nervous system tissues. Preclinical data have shown superior glycogen clearance and functional benefits compared to existing therapies, with plans to progress DYNE-401 into clinical trials.
- Discovery Programs: This segment encompasses early-stage research efforts to expand the FORCE platform’s application to additional neuromuscular diseases, including rare skeletal muscle disorders, cardiac and metabolic muscle diseases, and central nervous system indications. The company selectively explores strategic collaborations to maximize the platform’s potential and accelerate the development of novel therapies.
Dyne Therapeutics operates in the highly competitive neuromuscular disease space, where it competes with established pharmaceutical and biotechnology companies, as well as academic and research institutions. Key competitors in the DMD space include Sarepta Therapeutics, which markets four FDA-approved exon-skipping therapies and a gene therapy, as well as Wave Life Sciences, Entrada Therapeutics, and BioMarin Pharmaceuticals, all of which are developing exon-skipping or gene-editing therapies. In DM1, competitors include Avidity Biosciences, Pepgen, and Arrowhead Pharmaceuticals, which are advancing RNA-targeting therapies. For FSHD, competitors include Arrowhead Pharmaceuticals, Avidity Biosciences, and Roche Pharmaceuticals, while in Pompe disease, Sanofi and Amicus Therapeutics dominate the enzyme replacement therapy market. Dyne Therapeutics’ competitive advantage lies in its FORCE platform, which enables targeted delivery of therapeutic payloads to muscle and central nervous system tissues, potentially overcoming the limitations of existing therapies. The platform’s modularity allows for rapid development of candidates across multiple indications, while its demonstrated efficacy and safety in clinical trials position the company as a leader in the neuromuscular disease space.
Dyne Therapeutics serves patients with genetically driven neuromuscular diseases, including Duchenne muscular dystrophy, myotonic dystrophy type 1, facioscapulohumeral dystrophy, and Pompe disease. The company’s therapies target specific genetic mutations underlying these conditions, with a focus on addressing high unmet medical needs. While the filing does not disclose specific customer names, the primary end-users of Dyne Therapeutics’ potential products will be patients diagnosed with these rare and debilitating diseases, as well as the healthcare providers and institutions that treat them. The company’s commercial strategy includes building a targeted sales force to engage with neuromuscular disease specialists, patient advocacy groups, and payers to ensure broad access to its therapies upon approval.